CLP: And what are FDAs instructions for clinical laboratorians
Patients already on metformin HCl immediate-release (N=431) at a dose of at least 1500 mg per day were randomized after completing a 2-week, single-blind placebo run-in period
1 Introduction Polycystic ovary syndrome (PCOS) is a prevalent reproductive endocrine and metabolic disorder affecting 6-20% of women of reproductive age globally ( Systematic low-grade chronic inflammation (SLCI) plays a pivotal role in the pathogenesis of various chronic disorders, including PCOS
A plausible scenario, then, looks like this: Phase 3 primary completion in late 2025, NDA submission in the second half of 2025, FDA filing acceptance and review initiation in early 2026, and a PDUFA (Prescription Drug User Fee Act) action date likely in mid to late 2026
Unlike oral supplements, injected glutathione reaches the bloodstream intact, without degradation in the gastrointestinal tract